Abstract: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by persistent elevation of platelet counts due to clonal proliferation of megakaryocytes. It is relatively rare, with an estimated annual incidence of 1–2 cases per 100,000 individuals, and predominantly affects middle-aged and older adults, with a slight female predominance. Clinically, ET may be asymptomatic or present with vasomotor symptoms such as headache, dizziness, erythromelalgia, and visual disturbances; thrombotic and hemorrhagic complications are major concerns. Diagnosis is based on sustained thrombocytosis, bone marrow findings, exclusion of reactive causes, and detection of driver mutations such as JAK2, CALR, or MPL. Prognosis is generally favorable, with near-normal life expectancy in low-risk patients, though complications may impact outcomes. Management focuses on risk stratification, with low-dose aspirin for most patients and cytoreductive therapy, such as hydroxyurea, for high-risk individuals to prevent thrombotic events.

Keywords: Essential thrombocythemia, Epidemiology, Presentations, Pathophysiology, Diagnosis, Prognosis, Management.

Title: Basics of Essential Thrombocytopenia: A Teachers Note

Author: Chidinma Nkolika Ikeani, Silas Anayo Ufelle, Alphonsus Ogbonna Ogbuabor, Dorathy Chizoba Onovo

International Journal of Novel Research in Life Sciences                                                   

ISSN 2394-966X

Vol. 13, Issue 2, March 2026 – April 2026

Page No: 1-4

Novelty Journals

Website: www.noveltyjournals.com

Published Date: 15-April-2026